Key Takeaway: Alkermes plc has announced positive topline results from a Phase 1b study of ALKS 7290, a novel orexin 2 receptor agonist aimed at treating ADHD. The study assessed safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy volunteers and adults with ADHD. These results indicate a promising step forward in ADHD treatment options.
Market Sentiment Analysis
POSITIVE FACTORS
Positive topline results from Phase 1b study.
Demonstrated clinical proof-of-concept for ALKS 7290.
Evaluated in both healthy volunteers and adults with ADHD.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+29%
120-day peak, hindsight
Typical move
2.8%
average across 7 past catalysts
Lead asset
ALKS 2680
Phase 2 · Idiopathic Hypersomnia
Full Press Release Details
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced positive topline results from a phase 1 proof-of-concept study evaluating ALKS 7290, the company’s novel, investigational orexin 2 receptor (OX2R) agonist in development for the treatment of attention-deficit hyperactivity disorder (ADHD). The study evaluated the safety and tolerability (primary objective) and pharmacokinetics (PK) and pharmacodynamics (PD) of ALKS 7290 in healthy volunteers (n=88) and in adults with ADHD (n=5
Frequently Asked Questions
What are the results of the Phase 1b study for ALKS 7290?
The Phase 1b study showed positive topline results, indicating clinical proof-of-concept for ALKS 7290.
What is ALKS 7290 used to treat?
ALKS 7290 is being developed for the treatment of attention-deficit hyperactivity disorder (ADHD).
Who participated in the ALKS 7290 study?
The study involved 88 healthy volunteers and 5 adults diagnosed with ADHD.
What were the primary objectives of the study?
The primary objectives were to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ALKS 7290.